Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100423 · ClinicalTrials.gov registry record · Phase 2
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 2 study, sponsored by Paolo Caimi, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02100423 is a Phase 2 study that has completed, run by Paolo Caimi, MD. The registered enrollment target is 35 participants.
The verdict
NCT02100423, a Phase 2 study, has completed, sponsored by Paolo Caimi, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase II trial studies the efficacy (activity), and tolerability of curcumin and cholecalciferol combination in treating patients with previously untreated stage 0-II chronic lymphocytic leukemia or small lymphocytic lymphoma. Curcumin and cholecalciferol may prevent or slow the growth of cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DIETARY_SUPPLEMENT cholecalciferol
- DRUG curcumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-10-16 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100423
The ClinicalTrials.gov registry entry for NCT02100423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paolo Caimi, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02100423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100423 about?
NCT02100423 is a clinical study titled "Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". This phase II trial studies the efficacy (activity), and tolerability of curcumin and cholecalciferol combination in treating patients with previously untreated stage 0-II chronic lymphocytic leukemia or small lymphocytic lymphoma. Curcumin and cholecalciferol may prevent or slow the growth of cance...
What is the current status of trial NCT02100423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2014-10-16. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT02100423?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), cholecalciferol (DIETARY_SUPPLEMENT), curcumin (DRUG).
Who is sponsoring clinical trial NCT02100423?
This trial is sponsored by Paolo Caimi, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.